Two-way ANOVA showed a significant main effect for postnatal HFD treatment (p < 0.05), but not for maternal HFD/obesity in pPPARγ/PPARγ levels. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.